Standard BioTools gets Nasdaq notice for failing $1 minimum bid price rule

• Standard BioTools received a Nasdaq notice for failing the $1 minimum bid price rule after 30 straight business days below $1.
• Shares keep trading on the Nasdaq Global Select Market under LAB; no immediate impact on listing status.
• Deadline to regain compliance is Jan. 19, 2027, requiring a $1+ closing bid for at least 10 consecutive business days.
• Possible extra 180-day cure period if it transfers to the Nasdaq Capital Market; a reverse split remains an option.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Standard BioTools Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-316183), on July 24, 2026, and is solely responsible for the information contained therein.